LONDON The rush into T-cell immunotherapy continues, with Germany's Immatics Biotechnologies GmbH teaming up with MD Anderson Cancer Center in the formation of a $60 million U.S. subsidiary.
Immatics U.S. Inc. will bring together MD Anderson's cell therapy expertise with Immatics' Xpresident cancer peptide discovery technology, to develop both autologous and allogeneic treatments. The formation of the subsidiary is funded by $40 million from its parent company and a $19.7 million grant from the Cancer Prevention and Research Institute of Texas.
To date, Tuebingen, Germany-based Immatics has applied its Xpresident technology to the discovery of tumor-specific peptides as the basis of cancer vaccines. The lead